Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

Score over time

What counts as success

The trial's main goal(s), called the “primary outcome.”

• Part 1 - Occurrence of dose limiting toxicities (DLTs)

  Measured over: Up to 21 days after first dose of investigational medicinal product (IMP)

• Part 1 and Part 2 - Occurrence of pumitamig treatment emergent adverse events, treatment-related adverse events, treatment emergent serious adverse events, treatment-related serious adverse events, and adverse events of special interest

  Measured over: From initiation of the first dose of IMP to the 90-day Follow-Up visit

• Part 1 and Part 2 - Occurrence of dose interruption, dose reduction, and/or participant discontinuation due to adverse events

  Measured over: From initiation of the first dose of IMP until the 90-day Safety Follow-up visit

• Part 1 and Part 2 - Objective response rate

  Measured over: Up to approximately 2 years

Changes Tremor has spotted